Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
JAMA Cardiology
|
September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial
Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
Diabetes Care
|
November 18, 2022
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Rena Pollack, Itamar Raz, Stephen D Wiviott, et al.
The New England Journal of Medicine
|
September 1, 2025
Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia
Brian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.
Circulation
|
June 23, 2025
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
JAMA Cardiology
|
February 4, 2026
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
JAMA Cardiology
|
April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care
|
September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
David D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism
|
August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58
Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes Care
|
December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Avivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
European Journal of Heart Failure
|
December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58
Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
JAMA Cardiology
|
September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial
Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
Diabetes Care
|
November 18, 2022
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Rena Pollack, Itamar Raz, Stephen D Wiviott, et al.
The New England Journal of Medicine
|
September 1, 2025
Targeting <i>APOC3</i> with Olezarsen in Moderate Hypertriglyceridemia
Brian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.
Circulation
|
June 23, 2025
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
JAMA Cardiology
|
February 4, 2026
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
JAMA Cardiology
|
April 14, 2021
Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, et al.
Diabetes Care
|
September 18, 2021
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
David D Berg, Stephen D Wiviott, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism
|
August 27, 2020
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58
Avivit Cahn, Stephen D Wiviott, Ofri Mosenzon, et al.
Diabetes Care
|
December 18, 2019
Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study
Avivit Cahn, Ofri Mosenzon, Stephen D Wiviott, et al.
European Journal of Heart Failure
|
December 3, 2020
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58
Thomas A Zelniker, David A Morrow, Ofri Mosenzon, et al.
Page
of 11